key: cord-0684646-znq3l4j0
authors: Verd, Sergio; Fernández‐Bernabeu, Marisa; Cardo, Esther
title: The controversy surrounding vaccination of young people against COVID‐19
date: 2021-11-11
journal: Acta Paediatr
DOI: 10.1111/apa.16156
sha: fdd435008b51215649af5e8dfa646b2a4fbef3bb
doc_id: 684646
cord_uid: znq3l4j0

We agree with the view already expressed by Glikman et al.1 that Israel has gained world leadership in technology and capacity of COVID-19 vaccination. However, in these days of mandates on full vaccination of children against COVID-19, a sustained communication effort is required to reassert this leading position. Glikman et al. report that on May 2021, the CDC and the Israeli Ministry of Health (IMOH) concluded that the potential benefits of COVID-19 vaccination outweigh (…) the possible risk of peri-myocarditis. Subsequently, on 2 June 2021, the IMOH approved the vaccine for children and adolescents 12-15 years old.

We agree with the view already expressed by Glikman et al. 1 To summarise, we find ourselves wondering whether it is fair vaccinating all children. Should the two months follow-up required for emergency use authorisation be maintained instead of the one year period of study from vaccination, essential for full approval in clinical trials?

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The current work has no funding. 

Vaccinating children and adolescents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-The Israeli experience

SARS-CoV-2 mRNA vaccination-associated myocarditis in children ages 12-17: A Stratified National Database Analysis

Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting

The controversy surrounding vaccination of young people against COVID-19